Oncology · Precision Cancer Testing

Liquid Biopsy | cfDNA Assay
Non-invasive ctDNA Profiling

Liquid biopsy enables genomic analysis from circulating tumor DNA for therapy selection and disease monitoring.

Plasma/CSF/Urine
Sample Type
10–20 mL blood
Samples
~15 working days
Turnaround Time

Liquid Biopsy | cfDNA Assay at Nucleome Informatics

Non-invasive ctDNA Profiling

Why this Test Matters

Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.

Who Should Consider this Test

  • Insufficient tissue
  • Treatment monitoring
  • MRD
  • Recurrence

Applicable Cancer Types

Lung, Breast, Colorectal, Multiple solid tumors

What the test covers and delivers

What is Covered

  • SNVs
  • InDels
  • CNVs
  • Fusions

Clinical Utility​

  • Treatment selection
  • Prognostic and predictive biomarkers
  • Clinical trial matching
  • Identification of actionable alterations
  • Comprehensive clinical interpretation

Technology

Ultra-sensitive cfDNA sequencing

Test specifications

ParameterDetails
Sample TypePlasma/CSF/Urine
Samples10–20 mL blood
Turnaround Time~15 working days
Report IncludesVariant interpretation, therapy associations, clinically actionable biomarkers
QualityHigh-depth NGS with rigorous QC
Talk to our team. Email info@nucleomeinfo.com or call +91 40 40114169 to discuss sample requirements and turnaround for Liquid Biopsy | cfDNA Assay.